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BACKGROUND: Women aged 50–70 should receive
breast, cervical (until age 65), and colorectal cancer
(CRC) screening; men aged 50–70 should receive CRC
screening and should discuss prostate cancer screening
(PSA). PreView, an interactive, individually tailored Video
Doctor Plus Provider Alert Intervention, adresses all can-
cers for which average risk 50–70-year-old individuals are
due for screening or screening discussion.
METHODS: We conducted a randomized controlled trial
in 6 clinical sites. Participants were randomized to Pre-
View or a video about healthy lifestyle. Intervention group
participants completed PreView before their appointment
and their clinicians received a “Provider Alert.” Primary
outcomes were receipt of mammography, Pap tests (with
or without HPV testing), CRC screening (FIT in last year or
colonoscopy in last 10 years), and PSA screening discus-
sion. Additional outcomes included breast, cervical, and
CRC screening discussion.
RESULTS: A total of 508 individuals participated, 257 in
the control groupand251 in the intervention group. Screen-
ing rates were relatively high at baseline. Compared with
baseline screening rates, there was no significant increase
inmammography or Pap smear screening, and a nonsignif-
icant increase (18% vs 12%) in CRC screening. Intervention
participants reported a higher rate of PSA discussion than
did control participants (58% vs 36%: P < 0.01). Similar
increases were seen in discussions about mammography,
cervical cancer, and CRC screening.
CONCLUSION: In clinics with relatively high overall
screening rates at baseline, PreView did not result in sig-
nificant increases in breast, cervical, or CRC screening.
PreView led to an increase in PSA screening discussion.
Clinician-patient discussion of all cancer screenings sig-
nificantly increased, suggesting that interventions like
PreView may be most useful when discussion of the pros
and cons of screening is recommended and/or with pa-
tients reluctant to undergo screening. Future research
should investigate PreView’s impact on those who are
hesitant or reluctant to undergo screening.
TRIAL REGISTRATION: ClinicalTrials.gov: NCT02264782
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BACKGROUND
The United States Preventive Services Task Force (USPSTF)
recommends screening mammography every 2 years for women
aged 50 to 74, cervical cancer screening for women aged 50–64
every 3–5 years, and screening for colorectal cancer (CRC) for
those aged 50–75.1 The American Cancer Society (ACS), the
American College of Physicians (ACP), and others recommend a
shared decision-making approach to prostate cancer screening
(PSA).2 Although the USPSTF had recommended against PSA
screening, their revised guidelines recommend a shared decision-
making approach to PSA screening for men aged 55–69.3
Few cancer screening interventions address all screenings
for which an individual is due. Women aged 50–70 should
receive breast, cervical (until age 65), and CRC screening and
men aged 50–70 should receive CRC screening and a PSA
screening discussion.3–6
A successful cancer screening intervention must also (1) ad-
dress individual stage of change,7–9 (2) be tailored to address
individual barriers, and (3) support and simplify the clinician’s job.
The Transtheoretical Model posits that an individual
passes through a series of stages when deciding whether
or not to engage in a preventive behavior. The stages
include precontemplation—never thought about screening,
contemplation—thinking about screening, action—has
completed at least one screening in appropriate time
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frame, maintenance—has completed at least two appropri-
ate screening in appropriate time frame, or relapse—has
been screened in the past and is not planning to be
screened again.7–9
Barriers to receipt of screening can occur at the level of the
clinician, the patient, or the system.10 Overcoming barriers can
lead to completion of the preventive activity.
Since different individuals will be at different stages of
readiness and will have different barriers to screening, mes-
sages about screening should be individually tailored both to
an individual’s readiness and to his/her individual barriers to
screening. In addition, an intervention should not create addi-
tional work but rather should “support and simplify” what the
clinician is already doing.
We developed PreView, an Interactive Video Doctor inter-
vention that simulates interaction with a real clinician. Patients
are asked about readiness (based on the transtheoretical mod-
el) to undergo screening or screening discussion and individ-
ual barriers to screening. They receive individual tailored
messages based on stage of change and individual barriers.
The clinician receives a paper “Provider Alert” describing the
patient’s readiness and individual barriers as well as possible
responses that could facilitate overcoming the barriers.
We conducted a randomized controlled trial (RCT) com-
paring the impact of PreView, an Interactive Video Doctor
Plus Provider Alert Intervention, addressing all cancers for
which an individual was due for screening or screening dis-
cussion, with usual care. Primary outcomes were primary care
patients’ receipt of mammography, Pap tests, and CRC screen-
ing as well as discussions about PSA testing. Additional
outcomes included discussions about breast, cervical and
CRC screening.
METHODS
Intervention Sites
To ensure diversity, we intentionally chose a variety of
primary care sites. All are part of the San Francisco Bay
Area Collaborative Research Network, a primary health
care practice-based research network supported by the
UCSF Clinical and Translational Science Institute. Six
clinics agreed to participate. One clinic withdrew after a
short period: no participants from this clinic were includ-
ed. The clinic that withdrew wanted to try a model where
their staff members (rather than our research assistant)
implemented the intervention; however, it was difficult
to ensure intervention fidelity with this model and so we
mutually agreed to withdraw this clinic. An additional
clinic was recruited after this clinic’s withdrawal. The
final sites included three federally qualified health centers
(FQHCs), two large staff model private practices, and one
small physician owned and operated clinic associated with
a larger regional health organization.
Clinician Recruitment
The intervention was presented by clinic leaders as an inter-
vention in which each primary care clinic would participate.
Clinicians were told that they would potentially see patients in
both intervention and control groups. .After the patient com-
pleted PreView on the iPad, a paper “Provider Alert”would be
generated which the clinician could use if desired.
Although staff members were not formally recruited, we
told staff and providers that we would solicit ongoing input
about how to ensure the intervention ran as efficiently as
possible at their sites.
Patient Recruitment
Eligible patients were age 50–70 with upcoming follow-up or
preventive appointments. Patients whom clinicians deemed
inappropriate (e.g., dementia, medical conditions precluding
screening, or psychiatric illness) were not contacted. Partici-
pants were asked to come in early to ensure adequate time for
consent and program completion before scheduled
appointments.
Description of the PreView Plus Provider Alert
Intervention
PreView (Preventive Video Education in Waiting Areas) is an
interactive, multimedia “Video Doctor” plus Provider Alert
intervention that simulates a discussion between clinician and
patient. PreView is delivered on an iPad.
PreView starts with a welcome to the program and a series
of health and risk assessment questions, asking about prior
cancer screening (whether the person has ever been screened
or up to date with screening) and readiness to change cancer
screening behavior. Women are asked about breast, cervical,
and CRC screening tests and men are asked about CRC
screening tests and whether they have ever had a discussion
about PSA screening with their provider. Stage of change is
assessed according to the Transtheoretical Model of Behavior
Change (precontemplation, contemplation, action, mainte-
nance, or relapse) with respect to cancer screening and per-
ceived barriers to screening.9
The Video Doctor is then introduced and is designed to
simulate a conversation between a patient and a real physician,
including video and audio in order to provide a realistic
experience. The program uses branching logic in order for
individually relevant video clips to be shown according to the
participant’s previous answers.
The participant receives an individualized message from the
Video Doctor based on his/her stage of change for each cancer.
For example, for breast cancer, individuals who are
Precontemplators receive a message about the importance of
mammography, whereas individuals in Maintenance receive a
congratulatory message for taking care of their health. Partic-
ipants all receive information about the norms and recommen-
dations for screening for each cancer (based on USPSTF
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recommendations). Each individual is then asked about read-
iness to change. Individuals who are unsure or not ready
receive individualized messages from the Video Doctor about
the relevance, risks, and rewards of screening and then choose
from an extensive list of barriers or roadblocks to screening.
Perceived barriers to screening are based on our prior re-
search and the research of others11–13 and on published shared
decision-making models for prostate cancer screening.14, 15
They are specific for each cancer and include options such as
“I do not think I am at risk for breast cancer,” “I am concerned
that a Pap test will be painful or uncomfortable,” “I don’t need
to get tested [for CRC] because I don’t have any symptoms”
(see Box 1 for a complete list of barriers). The participant can
choose up to three roadblocks for each cancer. He/she then
receives an individualized message from the Video Doctor
tailored to each roadblock, including suggestions for overcom-
ing that roadblock.
MAMM mammography, PAP Pap smear: cervical cancer
screening module, CRC colorectal cancer screening module,
PSA prostate cancer screening discussion module
After the intervention, a paper “Provider Alert” is generat-
ed, which can be used by the clinician. This alert outlines the
participant’s stage of change, individual barriers to screening,
and offers potential individual suggestions for overcoming the
barriers.
We conducted a pilot study for feasibility and accept-
ability with 80 patients in 4 settings. The majority of
men and women were interested in discussing and re-
ceiving a screening test when it was next due. Addition-
ally, about 70% of all participants agreed or strongly
agreed that the information provided helped them decide
whether or not to be screened for breast, cervical, or
CRC, or whether to have a PSA screening discussion
with their providers.16
Barriers common to multiple modules
Barriers Modules*
I have a hard time seeing a doctor MAMM, PAP, CRC
I have questions for the doctor MAMM, PAP, CRC
I do not think I am at risk for [NAME OF CANCER] MAMM, PAP, CRC
I need more information about the test MAMM, PAP
My doctor did not recommend it MAMM, PAP, CRC
I have too many other health problems MAMM, PAP, CRC, PSA
I don’t have a regular doctor MAMM, PAP, CRC, PSA
Barriers unique to specific modules
Mammography:
Getting a mammogram regularly is a problem
Cervical Cancer Screening:
I would prefer to have a female do the Pap test but my doctor is a male
I am concerned that a Pap test will be painful or uncomfortable
I am concerned that a Pap test will be embarrassing
I need more information about HPV testing
Colorectal Cancer Screening:
I have concerns about sigmoidoscopy or colonoscopy:
I am concerned about discomfort
I am concerned that the test will be embarrassing
The test will take too long
I am too busy
I cannot take time off from work
I need transportation
I have childcare or eldercare problems
I am concerned that the test may be dangerous or unsafe
I do not have a referral for the test
I do not have a stool test kit
I have concerns about the stool test
Getting a stool test every year is a problem
My doctor did a rectal examination so I do not need the test
I don’t need it because I have a healthy lifestyle
I don’t need to get tested because I don’t have any symptoms
I am not sure what test to have
Prostate Cancer Screening Discussion:
My doctor did not bring it up
I am worried about the side effects of prostate cancer treatment
My doctor has in the past ordered PSA but did not discuss it
I have trouble understanding medical terms
I don't want to take up too much of the doctor's time
I have difficulty interrupting, disagreeing with, or expressing my opinion to the doctor
I have heard there is controversy about prostate cancer screening
I have questions for the doctor, or I am uncomfortable or embarrassed asking questions
MAMM = mammography 
PAP = Pap smear: cervical cancer screening module
CRC = colorectal cancer screening module
PSA = prostate cancer screening discussion module
Figure 1 List of perceived barriers to breast, cervical, colorectal, or prostate cancer screening
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Procedure
After the participant consented, he/she was guided to the iPad
located in the clinic waiting room and given headphones to
maintain privacy. He/she was randomized to the intervention
or the control group. All answered baseline questions. Partic-
ipants in the control group received information about healthy
diet and exercise while participants in the intervention group
received the PreView plus Provider Alert intervention.
Post-visit Assessment. After the visit, participants returned to
the iPad to answer a series of questions, which assessed
intention to change screening behavior, and whether each
cancer screening test was ordered or discussed during the
visit. Men were asked if they discussed PSA screening
during the visit. Intentions were measured on a 5-point Likert
Scale ranging from very unlikely to very likely.
Outcomes
Primary outcomes were being “up to date” with breast,
cervical, and CRC screening 14 months after the interven-
tion date. Although the earliest interval during which a
participant might be due would be 12 months, if he/she
was given a fecal immuochemical test at 12 months, he/
she would need time to complete it so we chose a 14-
month follow-up. Methods for determining whether a
participant was up to date with breast, cervical, and
CRC screening are described in Box 2. For PSA screen-
ing, the outcome was a discussion about the pros and cons
on the date of the study intervention as reported by the
patient. Receipt of prostate-specific antigen (PSA) alone
did not qualify as a discussion. Secondary outcomes in-
cluded readiness to discuss or engage in screening or
screening discussion for all cancers.
Outcomes were measured by chart review. All reviewers
were blinded to group assignment. If a screening test or
discussion was not documented in the chart, the participant
was contacted by phone. Participants were asked about
screenings they had over the past several years (depending
on which test). For example, some participants reported
colonoscopies that had taken place 6 years earlier that were
not in the records of the primary care clinician.
If the participants said that he/she had not had the tests
or discussion, this was documented. If he/she indicated
that she had the test or discussion, then the participant was
asked where he/she had the test. With the participant’s
permission, medical records were requested from the out-
side institution.
Since we intentionally conducted the intervention in 6
diverse sites, all with different record keeping systems, the
approach to record review was slightly different in each set-
ting. Some settings had paper charts and then transitioned to
an electronic health record (EHR) over the course of the study,
while others changed EHR systems over the course of the
study. We reviewed electronic and when appropriate, paper
records, to ensure full data collection.
Our primary outcome was being up to date with the
screening test as documented by any measure (including
self-report). We also performed a secondary analysis using
only outcomes that were validated by chart review. Addi-
tional secondary outcomes included readiness to be
screened or to discuss screening as measured by partici-
pant responses during the post-visit assessment.
Excluded from screening: Definition of “up to date”: Accepted documentation:
Mammography Women with history of 
double mastectomy prior to 
baseline or follow-up date
Receipt of bilateral 
mammogram within two years 
prior to baseline or follow-up 
date
Scanned report in EHR
Printed report in paper record
Patient self-report documented 
in the EHR or paper chart
Pap Smear with or 
without HPV co-
testing
Women who self-reported a 
past hysterectomy during 
enrollment at baseline date
Women who were 66 years 
of age or older at follow-up
Women with history of 
cervical cancer prior to 
baseline date
Receipt of pap smear within 
three years prior to baseline or 
follow-up date OR receipt of 
pap smear with HPV co-testing 
within five years prior to 
baseline or follow-up date
Scanned report in EHR
Printed report in paper record
Patient self-report documented 
in the EHR or paper chart 
Colorectal Cancer 
Screening
No exclusion criteria Receipt of stool test (FOBT or 
FIT) within fourteen months 
prior to baseline or follow-up 
date OR receipt of 
sigmoidoscopy within five years 
prior to baseline or follow-up 
date OR receipt of colonoscopy 
within ten years prior to 
baseline or follow-up date
Scanned report in EHR
Printed report in paper record
Patient self-report documented 
in the EHR or paper chart
Prostate Cancer 
Screening 
Discussion
Men with a history of 
prostate cancer or under 
active surveillance for 
prostate specific antigen 
levels prior to baseline date
Discussion of pros and cons of 
prostate specific antigen testing 
with clinician on baseline date 
Patient self report through 
post-visit questions 
administered after appointment 
on baseline date
Figure 2 Definitions of “Up to Date” with breast, cervical, colorectal screening and prostate cancer screening discussion at baseline or follow-up
date
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Analysis
Statistical analysis was performed using SAS version 9.4.17
Descriptive statistics were computed for all measures, includ-
ing means, standard deviations, and percentages, separately
for control and intervention subgroups. Items measuring how
likely the patient would discuss were dichotomized into “like-
ly” vs. “not likely,” those measuring beliefs and attitudes were
collapsed into “agree” and “disagree,” and those measuring
intention, into “likely” and “unlikely.” For those measures
defined as “yes,” “no,” or “don’t know,” don’t know responses
were included in the “no or don’t know” category for analyses.
We analyzed baseline data to explore differences in demo-
graphic factors and and in the outcomes between control and
intervention groups.
We also used linear models with a normal link function to
determine any difference between the two groups of the
change in proportion from pre to post-intervention. To further
evaluate changes from baseline to post-intervention, we used
generalized linear models with a logit link function on binary
outcomes while adjusting for baseline values and for age of the
participants as a potential covariate. We adjusted for gender
differences.
We report descriptive statistics and P values for the group
differences for each of the outcomes. A significance level of
0.05 was used for all statistical tests.
Table 1 Description of Participants from Six Diverse Clinical Sites
Randomized to Intervention and Control Groups
Control
(n = 257)
Intervention
(n = 251)
P
value*
Age
Mean age at intervention 58.8 58.9 0.8
Gender, n (%)
Female 156
(60.7%)
150 (59.8%) 0.8
Race, n (%)
*Participants could choose
more than
one race
0.6
American Indian or
Alaskan Native
9 (3.5%) 11 (4.4%)
Asian or other Pacific
Islander
26
(10.1%)
23 (9.2%)
Black or African-American 93
(36.2%)
83 (33.1%)
White 127
(49.4%)
137 (54.6%)
Some other race 22 (8.6%) 21 (8.4%)
Hispanic/Latino, n (%)
Yes 23 (8.9%) 25 (10%) 0.7
Language, n (%)
English 236
(91.8%)
230 (91.6%) 0.8
Spanish 7 (2.7%) 9 (3.6%)
Other 14 (5.4%) 12 (4.8%)
Marital status, n (%)
Married/living with do-
mestic partner
108 (42%) 125 (49.8%) 0.1
Other 149 (58%) 126 (50.2%)
Education, n (%)
High school graduate or
less
110
(42.8%)
123 (49%) 0.2
College or more 147
(57.2%)
128 (51%)
Employment status, n (%)
Working full or part time 96
(37.4%)
95 (37.8%) 0.9
Other 161
(62.6%)
156 (62.2%)
Health insurance status, n (%)
Does not have health
insurance
21 (8.2%) 13 (5.2%) 0.2
Has health insurance 236
(91.8%)
238 (94.8%)
Among those with health insurance, n (%)
*Participants could choose more than
one type of health insurance
Medicare 96
(40.7%)
95 (40%) 0.8
Medicaid 26 (11%) 27 (11.3%)
Private insurance/
managed care insurance
130
(55.1%)
125 (52.5%)
Other/not sure what type 31
(13.1%)
36 (15.1%)
Self-rated health, n (%)
Poor 16 (6.6%) 17 (6.8%)
Other 241
(93.8%)
234 (93.2%)
Health decision-making
preference, n (%)
0.9
Mostly make the decision
myself
115
(44.7%)
113 (45%)
Make decision with my
doctor
118
(45.9%)
116 (46.2%)
Doctor mostly makes the
decision
24 (9.3%) 22 (8.8%)
*P < 0.05 indicates significant difference
Table 2 Primary Cancer Screening Outcomes Among Participants
in the Preview Randomized Controlled Trial
Control Intervention P
value*
Mammography n = 156 n = 150
Baseline, n (%) 113
(72.4%)
121 (80.7%)
Follow-up, n (%) 123
(78.9%)
127 (84.7%)
Change + 6.4% + 4% 0.48
Pap smear (with or without
HPV co-testing)
n = 108 n = 84
Baseline, n (%) 73
(67.6%)
62 (73.8%)
Follow-up, n (%) 88
(81.5%)
71 (84.5%)
Change + 13.9% + 10.7% 0.89
Colorectal cancer screening n = 257 n = 251
Baseline, n (%) 168
(65.4%)
152 (60.6%)
Follow-up, n (%) 198
(77%)
197 (78.5%)
Change + 11.6% + 17.9% 0.31
Prostate cancer
screening discussion
n = 101 n = 101
Baseline, n (%) N/A N/A
Follow-up, n (%) 36
(35.6%)
58 (58%) < 0.01*
Change N/A N/A
*Using a linear model to compare whether the follow-up rates are
different between control and intervention while adjusting for baseline
screening rates, age, and gender where appropriate (except for prostate
cancer screening discussion which lacked a baseline rate)
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RESULTS
There were no significant baseline differences between
the intervention and control groups (Tables 1 and 2). The
average age of participants was 59 and, as is typical in
primary care clinic settings, there were more women than
men (60% compared with 40%). Over one-third of par-
ticipants were African-American and approximately 10%
were Asian. Just less than half (46%) had a high school
education or less. The majority had health insurance;
approximately half of participants had private health in-
surance and approximately 40% had MediCare. Slightly
less than a third of participants rated their health as fair
or poor.
Primary Outcomes. We compared screening rates at
baseline and follow-up. For mammography, the baseline
rate of being up to date in the intervention group was
80.8% compared with the 72.4% in the control group (P =
NS). The rate in the control group increased by 6% versus
4% in the intervention group, a difference that was not
statistically significant. Similarly, for cervical cancer, the
baseline rate was higher in the control group than in the
intervention group (73.8% vs 67.6%: P = NS). The rate in
the control group increased by 13.9% whereas that in the
intervention group increased by 10.7%, a difference that
was not statistically significant. For CRC screening, the
baseline rate was nonstatistically higher in the control
group (65% vs 61%). CRC screening rates increased by
17.9% in the intervention group and 11.7% in the control
group; this difference was not statistically significant.
We do not have baseline rates of prostate cancer screening
discussion, because discussion is not routinely documented in
a systematic way. Participants were asked during the post-visit
Table 3 Comparison of Participant Responses to Post-visit Ques-
tions Between Control and Intervention Groups
Control Intervention P
value*
Mammography n = 101 n = 102
When you met with your
doctor today, did you discuss
having a mammogram?
Yes, n (%) 88
(56.4%)
110 (73.8%) < 0.01*
When you met with your
doctor today, did you discuss when
you should get your next mammogram?
Yes, n (%) 84
(53.9%)
106 (71.1%) < 0.01*
Readiness to be tested
Green: Ready to be tested,
n (%)
130
(83.3%)
139 (93.3%) < 0.03*
Yellow: I think I would like
to be tested, n (%)
7 (4.5%) 3 (2.0%)
Red: I don’t want to be
tested, n (%)
19
(12.2%)
7 (4.7%)
Pap smear (with or without
HPV co-testing)
n = 147 n = 161
When you met with your doctor
today, did you discuss having a Pap test?
Yes, n (%) 54
(49.1%)
67 (74.4%) < 0.01*
When you met with your doctor
today, did you discuss when you
should get your next Pap test?
Yes, n (%) 54
(49.1%)
64 (71.1%) < 0.01*
Readiness to be tested
Green: Ready to be tested,
n (%)
86
(78.2%)
84 (93.3%) < 0.01*
Yellow: I think I would like
to be tested, n (%)
12
(10.9%)
3 (3.3%)
Red: I don’t want to be
tested, n (%)
12
(10.9%)
3 (3.3%)
Colorectal cancer screening n = 257 n = 251
When you met with your doctor
today, did you discuss having a test
for colon cancer screening?
Yes, n (%) 150
(58.4%)
184 (73.9%) < 0.01*
When you met with your doctor
today, did you discuss when you
should get your next test for colon
cancer screening?
Yes, n (%) 138
(53.7%)
170 (68.3%) < 0.01*
Readiness to be tested
Green: Ready to be tested,
n (%)
196
(76.3%)
220 (88.4%) < 0.01*
Yellow: I think I would like
to be tested, n (%)
23 (8.9%) 11 (4.4%)
Red: I don’t want to be
tested, n (%)
38
(14.8%)
18 (7.2%)
Prostate cancer screening
discussion
n = 156 n = 151
After meeting Dr. Summers on our waiting room video program and
after visiting with your own doctor in person today, how likely are you
to ask your doctor about the pros and cons of PSA testing?
Somewhat likely/very
likely, n (%)
75
(74.3%)
88 (88%) 0.02*
Readiness to discuss testing
Green: Ready to discuss
testing, n (%)
64
(63.4%)
74 (74%) < 0.12
Yellow: I think I would like
to be tested, n (%)
18
(17.8%)
17(17%)
Red: I don't want to be
tested, n (%)
19
(18.8%)
9 (9%)
*P value is based on chi-square or Fisher’s exact test with a value <
0.05 indicating a significant difference between control and intervention
groups
Table 4 Secondary Analyses Focusing on Cancer Screening
Outcomes Only Those with Documented Screening
Control Intervention P
value*
Mammography n = 156 n = 150
Baseline, n (%) 112
(71.8%)
120 (80%)
Follow-up, n (%) 122
(78.2%)
126 (84%)
Change + 6.4% + 4% 0.50
Pap smear (with or without
HPV co-testing)
n = 103 n = 79
Baseline, n (%) 70 (68%) 58 (73.4%)
Follow-up, n (%) 70 (68%) 56 (70.9%)
Change + 0 − 2.5% 0.89
Colorectal cancer screening n = 257 n = 251
Baseline, n (%) 167
(65%)
151 (60.2%)
Follow-up, n (%) 194
(75.5%)
196 (78.1%)
Change + 10.5% + 17.9% 0.21
*Using a linear model to compare whether the documented follow-up
rates are different between control and intervention while adjusting for
baseline screening rates, age, and gender where appropriate (except for
prostate cancer screening discussion which lacked a baseline rate)
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assessment “When you met with your doctor today, did you
discuss the pros and cons of PSA testing?” Significantly more
intervention participants than control participants reported
PSA discussion (58% vs 36%: P < 0.01).
Cancer Screening Discussions. In Table 3, we describe
participant responses to questions asked during the post-visit
assessment. Intervention group participants were significantly
more likely to discuss having a mammogram, to discuss when
next to get a mammogram, and to indicate more readiness to
be screened. Similarly, intervention group participants de-
scribed more discussion about having a Pap test and when
next to have a Pap test and CRC screening and when next to
have CRC screening. More intervention group participants
indicated that they discussed PSA screening and that they
would be likely to ask their doctor about the pros and cons
of PSA screening at their next visit.
Staff and Provider Input. We collected ongoing feedback
from staff members and providers to ensure that PreView
could be implemented efficiently in their settings. Staff
members did not feel that it interfered with clinical flow and
providers did not feel that it added any additional work.
DISCUSSION
Primary care clinicians address multiple medical issues and
also try to ensure that all health care maintenance items are
addressed for a particular patient. PreView is unique in that it
targets all cancers for which an individual participant is due
(Table 4). In addition, the messages are individually tailored
both to stage of change and to individual barriers to screening
or discussion.
Screening rates were relatively high at baseline in these
participating clinics, making it harder to see increases in
screening. The increase in screening rates was higher among
clinics with lower baseline rates (Supplemmentary Tables 5
and 6), suggesting that the ceiling effect had an important
contribution.
Discussion of mammography, cervical cancer screening,
and CRC screening increased in all intervention group
participants. This may be less relevant in those who are
planning to obtain screening anyway, but could potentially
have a larger impact in individuals who are not sure at
about whether or not to be screened. Given logistic issues
in the various clinical settings, we were unable to select
participants based on whether or not they were due for
screening, but this may be a useful future tactic for iden-
tifying who is most likely to benefit from PreView.
For prostate cancer, the main outcome was discussion
of the pros and cons of screening, as discussion of the
pros and cons of screening is currently recommended by
multiple organizations.2 Measuring discussion is more
difficult than measuring whether a screening test is or-
dered. Our primary prostate cancer screening outcome was
“Discussion of the pros and cons of PSA testing” as
reported by the participant after the visit. Intervention
group participants were significantly more likely to report
discussion of PSA testing and were more likely to indicate
intent to discuss PSA testing at the next visit.
Our study had several limitations. High baseline screen-
ing rates made it harder to see increases in screening rates.
We were unable to select only those patients with upcom-
ing appointments who were due for a screening, thus po-
tentially including individuals who were already up to date
with screening. Finally, since “discussion” of the pros and
cons of PSA testing is inconsistently documented in clini-
cal charts, we were unable to measure baseline rates of PSA
discussion or to validate participants self-report by review
of the medical records. However, the large difference be-
tween intervention and control seems unlikely to have
occurred by chance.
PreView was most useful for those interventions where dis-
cussion was the outcome, such as decision-making about pros-
tate cancer screening and could potentially be quite useful in
encouraging discussion in those who are reluctant to be
screened for other cancers. Interventions like PreView may also
be useful in situations where discussion and shared decision-
making are encouraged, such as mammography screening for
women in their forties and those aged 75 and older.5
PreView, the interactive Video Doctor plus Provider Alert
intervention, led to more discussion about screening and more
readiness to be screened. It may also be useful in advancing
individuals along the stages of change toward readiness to be
screened or to discuss screening.18, 19 There are many areas of
primary care where there is not a single course of action, where
shared decision-making is encouraged, and interventions like
PreView which focus on stage of change and perceived bar-
riers to screening or discussion can have a real impact.
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